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Objectives Following up the SLE GWAS identification of NMNAT2 at rs2022013, we fine-
mapped its 150kb flanking regions containing NMNAT2 and SMG7 in a 15,292 case-control 
multi-ancestry cohort and tested functions of identified variants. 
Methods We performed genotyping using a custom array, imputation by IMPUTE 2.1.2, and 
allele specific functions using qRT-PCR and luciferase reporter transfections. SLE PBMCs were 
cultured with siRNAs to measure antinuclear antibody (ANA) and cyto/chemokine production in 
supernatants using ELISA.  
Results We confirmed association at NMNAT2, and identified an independent signal at SMG7 
tagged by rs2702178 in European Americans (EA) only (P=2.4×10-8, OR=1.23 [95%CI=1.14-
1.32]). In complete linkage disequilibrium with rs2702178, rs2275675 in the promoter region 
robustly associated with SMG7 mRNA levels in multiple expression quantitative trait loci 
datasets. The risk allele of rs2275675 was dose-dependently associated with decreased SMG7 
mRNA levels in PBMCs of 86 SLE patients and 119 controls (P=1.1×10-3 and 6.8×10-8, 
respectively) and conferred reduced transcription activity in transfected HEK-293 and Raji cells 
(P=0.0035 and 0.0037, respectively). As a critical component in the nonsense-mediated mRNA 
decay pathway, SMG7 could regulate autoantigens including RNP and Sm. We showed SMG7 
mRNA levels in PBMCs correlated inversely with ANA titers of SLE patients (r=-0.31, P=0.01), 
and SMG7 knockdown increased production of ANA and CCL19 in SLE PBMC cultures 
(P=2.0×10-5 and 2.0×10-4, respectively).  
Conclusions We confirmed NMNAT2 and identified independent SMG7 association with SLE. 
The inverse relationship between levels of the risk-allele associated SMG7 mRNAs and ANAs 




Systemic lupus erythematosus (SLE) is a prototype autoimmune disease characterized by 
autoantibody production resulting in tissue injury of multiple organs. A combination of genetic, 
epigenetic and environmental factors contributes to the pathogenesis of SLE. Recent genome-
wide association studies (GWAS) have identified more than 50 susceptibility loci for SLE [1]. 
There is an ongoing effort to fine map these risk loci and to gain insights how they work to 
influence lupus manifestations. 
Within the 1q25 region, rs2022013 located in the first intron of NMNAT2 (encoding 
nicotinamide mononucleotide adenylyltransferase 2) was associated with SLE in the GWAS 
conducted by the International Consortium for Systemic Lupus Erythematosus Genetics 
(SLEGEN) (P=1.1×10-7, OR=0.85) and in a large-scale replication study (P=1.5×10-3, OR=0.92) 
using subjects of European ancestry [2, 3], suggesting NMNAT2 as a SLE risk locus. NMNAT2 
is a central enzyme of the nicotinamide adenine dinucleotide (NAD) biosynthetic pathway and 
mainly expressed in brain with a known function of delaying axon degeneration [4, 5]. Given no 
apparent clues for its involvement in immune dysregulation, we fine mapped this novel NMNAT2 
locus and neighboring genes for association with SLE in subjects from four ancestries.  
In this study, we confirmed NMNAT2 association with SLE susceptibility and identified 
independent association signals at the SMG7 region in European American (EA). SMG7, 
located approximately 50 kb 5’ of NMNAT2, encodes a component essential for nonsense-
mediated mRNA decay (NMD) that controls mRNA quality, regulates gene expression and 
maintains genome stability [6]. We detected the SLE-risk alleles associated with decreased 
SMG7 mRNA levels in peripheral blood mononuclear cells (PBMCs) of both SLE and healthy 
control subjects, and an inverse correlation between antinuclear autoantibody (ANA) titers and 
SMG7 mRNA levels in SLE patients. SMG7 reduction increased production of ANA and 
chemokine (C-C motif) ligand 19 (CCL19) in SLE PBMC cultures, suggesting that decreased 
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SMG7 expression impacts the NMD pathway mediated mRNA surveillance, contributing to 








DNA from individuals participating in Large Lupus Association Study 2 (LLAS2) recruited from 
multiple sites was processed at the Oklahoma Medical Research Foundation (OMRF). Each 
institution had Institutional Review Board (IRB) approval to recruit subjects and the overall study 
was approved by the IRB of OMRF. All SLE patients met American College of Rheumatology 
revised criteria for the classification of SLE [7]. 
 
Genotyping and quality control 
Genotyping was performed using an Illumina custom bead array on the iSCAN instrument for 35 
tag SNPs covering over 200kb of the NMNAT2-SMG7 region and 347 admixture informative 
markers (AIMs). SNPs meeting the criteria as described [8] were included for subsequent 
genetic association tests. 
Subjects with missing genotype rate >10%, shared identity by descent >0.4, or gender 
mismatch were removed. Global ancestry was estimated based on the genotype of AIMs, using 
principal components analysis [9] and ADMIXMAP [10] as described [11] and genetic outliers 
removed. Final clean data were from 15,292 unrelated subjects including EA, African Americans 
(AA), Asians (AS) and Hispanics enriched for Amerindian-European admixture (HS). 
 
Imputation 
Imputation was performed using IMPUTE 2.1.2 [12], with SNP and INDEL genotypes from the 
1000 Genomes Project (version 3, Phase 1 integrated data, March 2012 release) as references. 
Imputed genotypes with information scores >0.9 and MAF >0.01 were further analyzed.  
 
Quantitative real-time PCR 
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Total RNAs were purified using the AllPrep DNA/RNA mini kit (Qiagen) from PBMCs of EA 
subjects and reverse-transcribed into cDNA with the SuperScript II Reverse Transcriptase kit 
(Life Technologies). Transcript levels of SMG7, SMG7-AS1 and a housekeeping gene RPLP0 
were measured in triplicates by quantitative real-time PCR using TaqMan assays (SMG7: 
Hs00539224_m1, RPLP0: Hs99999902_m1; Life Technologies), and their relative levels were 
calculated by the 2-ΔΔCt method and Log10 transformed. 
Autoantibody profiles of 68 SLE patients (including ANA, anti-dsDNA or antibodies to 
extractable nuclear antigens) were measured in the UCLA clinical laboratory at the time of blood 
draw, and these data were used to correlate with SMG7 mRNA levels in PBMCs. 
 
Plasmid construction and luciferase reporter assay 
DNA sequences (0.3kb) surrounding rs2275675 or rs10911339 were PCR amplified using 
genomic DNA from homozygous subjects for the C allele (rs2275675) and the T allele 
(rs10911339) using following primers: 
 rs2275675, 5’-GGGGTACCGTAGAAAGAAAAGCAGAAC-3’ (forward) and 5’-
GAAGATCTGAGACCTGCACCAATAAG-3’ (reverse); rs10911339, 5’-
GGGGTACCGGTATGGGTGCCTAGC-3’ (forward) and 5’-
GAAGATCTCCAGGTGTGCAGACTTC-3’ (reverse). The PCR products were digested using 
restriction enzymes Kpnl and Bglll and inserted into the pGL3-promoter luciferase reporter 
vector (Promega). The vectors for the other allele were made using the QuikChange Lightning 
Site-Directed Mutagenesis Kit (Stratagene). All constructs were sequenced to assure proper 
orientation and authenticity in the vector. 
HEK-293 (human embryonic kidney cell line) and Raji B cells were obtained from the 
American Type Culture Collection. HEK-293 cells were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% FBS, seeded on a 24-well plate at a concentration of 
2×105 cells/well and transiently transfected using Lipofectamine 2000 (Life Technologies) with 1 
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μg of rs2275675 vector (C or T), rs10911339 vector (C or T) or empty vector (pGL3-promoter) 
and 100 ng of pRL-SV40 vector (Renilla luciferase) as an internal control. Raji cells were grown 
in RPMI 1640 medium with 10% FBS, seeded on 24-well plates at a concentration of 2×106 
cells/well and electroporated with 5μg of luciferase report constructs and 100 ng of Renilla 
control vector on a nucleofector device (Amaxa). The luciferase activity in total cell lysates was 
measured after 24 hours using a dual luciferase reporter assay system (Promega).  
 
RNA Interference 
Gene silencing by small interfering RNAs (siRNAs) was performed using the Accell® siRNA 
technology which achieves effective gene silencing in human primary cells without transfection 
reagents or viruses [13]. Pool of four siRNA sequences targeting SMG7 was designed and 
synthesized by Dharmacon (SMG7 siRNA SMARTpool E-021305). Pool of siRNAs targeting 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; SMARTpool D-001930) was used as a 
positive control, and the non-targeting control pool (D-001910) designed to have minimal 
targeting of known genes in human cells was used as a negative control. 
PBMCs from 13 SLE patients were isolated by Ficoll-Hypaque discontinuous gradient, 
resuspended in Accell delivery media plus 3μM siRNA, distributed to 96-well plate at 2×105 
cells/well, and divided into SMG7 silence group, GAPDH silence group (positive control), non-
targeting group (negative control) and mock group (medium only) (n=6 per group for each 
sample). Cells were incubated at 37°C with 5% CO2 for 5 days, then supernatants were 
collected and cells were harvested. Specific inhibition efficacy of SMG7 and GAPDH was 
confirmed by quantitative PCR. 
 
Enzyme-linked immunosorbent assay (ELISA) 
10 
 
ANA, CCL19, chemokine (C-X-C motif) ligand 10 (CXCL10), interleukin 6 (IL-6), IL-17, B-cell 
activating factor (BAFF) and interferon α (IFN-α) levels in supernatants were measured by 
ELISA kits (R&D Systems). 
 
Statistical analysis 
Allelic association test and conditional haplotype-based association test in each ancestral group 
were performed under a logistic regression model adjusted for gender and the first three 
principal components estimated using AIMs. The Bonferroni corrected P-value threshold was 
adjusted to P<1×10-3 on the basis of the maximum number of tests across all populations (49 
independent variants with r2<0.8). For trans-ancestral meta-analysis, a fixed effect model was 
applied if Cochran's Q statistic showed no evidence of genetic heterogeneity among odds ratios 
(P>0.05); otherwise, a random effect model was used. Association analyses were performed 
using PLINK v1.07 [14]. Pairwise LD values between SNPs were calculated using Haploview 
4.2 [15]. For comparing the results between two groups, Student’s t-test was conducted if the 
variance was normally distributed, whereas the Mann-Whitney U test was used if the variance 
was not normally distributed. Correlation between groups was evaluated using the Pearson rank 






To fine map the NMNAT2 region, we conducted genotyping and imputation for genetic variants 
(SNPs/INDELs) within a 308 kb region at 1q25 containing genes LAMC2, NMNAT2, SMG7-AS1 
and SMG7. After applying quality control measures, 35 genotyped and 85 to 278 imputed SNPs 
(varying among different ancestries) were assessed for association with SLE in 15,292 
unrelated case-control subjects from four ancestral groups: EA (3,438 SLEs vs. 3,417 controls), 
AA (1,679 vs. 1,934), AS (1,265 vs. 1,260) and HS (1,492 vs. 807) under a logistic regression 
model adjusting for gender and global ancestry (Figure 1). 
 
The association of NMNAT2 with SLE was confirmed in EA and HS ancestries  
In the largest EA dataset, 135 SNPs spanning the entire NMNAT2 were significantly associated 
with SLE after Bonferroni correction (P<1.0×10-3) for multiple comparisons (Figure 1B and Table 
S1). The SLE association at rs2022013 previously identified in the SLEGEN GWAS was 
confirmed in our EA subjects (minor allele frequency [MAF] 38.1% in cases vs. 42.4% in 
controls, P=3.9×10-7, OR=0.83 [95%CI=0.77-0.89]). Rs12146097 in the NMNAT2 (NM_015039) 
intron 1 exhibited the strongest signal exceeding the GWAS significance level (16.7% vs. 12.9%, 
P=1.5×10-10, OR=1.38 [95%CI=1.25-1.53]).  
In the HS dataset, significant associations with SLE were localized within the NMNAT2 
intron 1 after Bonferroni correction, with rs536586 showing the best signal (44.2% vs. 39.2%, 
P=2.7×10-4, OR=1.26 [95%CI=1.11-1.43]) (Figure 1B and Table S2). However, association of 
rs2022013 with SLE was not significant in HS (P=0.11). 
In the AA and AS datasets, we observed only weak association at SNPs in the NMNAT2 
region (P<0.05) and none reached the Bonferroni-corrected significance level (Figure 1B and 
Table S3&S4). 
Comparing across EA and HS, 8 SNPs (P<1.0×10-3) within a ∼51 kb interval in the 
NMNAT2 intron 1 showed consistent association with SLE in both EA and HS datasets, of which 
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6 SNPs (rs564146, rs681054, rs664422, rs502870, rs548292 and rs12146097, named as group 
1) each showed a Pmeta<5×10-8 in the trans-ancestral meta-analysis (Figure 1C and Table S5). 
Except rs12146097, the other 5 SNPs were in strong pairwise linkage disequilibrium (LD) with 
each other (r2≥0.99, D’=1.0) and with rs2022013 (r2≥0.83, D’≥0.96) in both EA and HS. In 
conditional haplotype-based association testing, conditioning on group 1 SNPs eliminated or 
reduced all other association signals in the NMNAT2 region to baseline in HS, but revealed 
residual association in EA predominantly in the region 55 kb downstream within the NMNAT2 
intron 1 to intron 3 (2.7×10-4≤Pc≤6.7×10-4) (Table S1&S2). These results confirmed NMNAT2 as 
a risk locus for SLE in EA and HS ancestries. 
 
Independent association of SMG7 with SLE in EA only 
In EA, 21 SNPs located at ~32kb 5’ of NMNAT2 (named as group 2, Figure 1B) were strongly 
associated with SLE (2.4×10-8≤P≤4.3×10-7), of which rs2702178 in the SMG7 intron 1 showing 
the best signal (40.8% vs. 36.2%, P=2.4×10-8, OR=1.23 [95%CI=1.14-1.32]) (Table S1). All 21 
SNPs were in strong LD with each other (r2≥0.98, D’≥0.99), but in low LD with group 1 SNPs 
(r2≤0.22, D’≤0.73). Genetic effects of NMNAT2 (group 1) and SMG7 (group 2) appear to be 
independent in EA using the conditional testing, in which association signals detected at either 
group of SNPs retained significance when conditioning on another group (Figure S1). Unlike the 
findings in EA, SNPs in the SMG7 region exhibited modest association with SLE (7.5×10-
3≤P≤0.02) in HS and none passed the Bonferroni-corrected significance level (Table S2). The 
SMG7 region was not well imputed in AA and AS datasets, which might explain their lack of 
significant associations (Table S3&S4). Taken together, we identified multiple SNPs in the 
SMG7 region showing independent association with SLE in EA dataset only. 
 
The SLE-associated SNPs identified in EA showed allelic differences in SMG7 expression 
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Given group 1 (5.5kb at intron 1 of NMNAT2) and group 2 SNPs (97kb from promoter to 
intron 17 of SMG7) located in the non-coding regulatory regions, we assessed their potential 
functions using the UCSC Genome Browser (Figure S2). While group 1 SNPs showed low or 
modest overlap with regulatory elements, group 2 SNPs (especially rs2275675 at the promoter 
and rs10911339 in intron 1, r2=1) were located in a region containing the H3K4Me3/H3K27Ac 
epigenetic marks for promoter/enhancer activity and overlapped with DNase hypersensitivity 
and transcription factor binding signals, suggesting that these identified SNPs might affect 
nearby genes expression. 
We checked the expression quantitative trait locus (eQTL) datasets [16-20] to evaluate 
allelic differences in the expression of genes located in nearby +/- 250 kb region, including 
LAMC1, LAMC2, NMNAT2, SMG7-AS1, SMG7, NCF2, ARPC5, APOBEC4 and RGL1. Both 
group 1 and group 2 SNPs were consistently associated with differential expression of SMG7 in 
diverse cell types from European-derived donors, including fibroblasts, adipocytes, 
lymphoblastoid cell lines, peripheral blood cells, primary T, B cells and monocytes. Compared to 
group 1 SNPs, group 2 SNPs (tagged by rs10911353 or rs2275675) showed stronger eQTL 
effects that the SLE-risk alleles were associated with decreased SMG7 levels (Table S6). The 
SLE-associated SNPs exhibited no eQTL evidence for the neighboring genes LAMC1, LAMC2, 
NMNAT2, SMG7-AS1, APOBEC4 and RGL1, or only weak effects on genes NCF2 and ARPC5, 
if at all, in blood cell types. Although expressed in the brain predominately, no eQTLs were 
reported at the NMNAT2 locus in studies from human brain tissues, including cortex, caudal 
pons, cerebellum, thalamus and hippocampus [21-29]. Surprisingly, in addition to immune cell 
types, cis associations between SLE-risk SNPs and SMG7 expression were also identified in 
brain tissues [24, 25], suggesting that modulation of expression levels is a likely functional 




Dose-dependent association between the SLE-risk allele of rs2275675 and decreased 
SMG7 levels  
We sought further evidence supporting the eQTL findings by assessing the association 
of rs12146097 and rs2275675 with SMG7 mRNA levels in PBMCs from 86 SLE patients and 
119 controls of European ancestry. Consistently, the SLE-risk C allele of rs2275675 was dose-
dependently associated with decreased SMG7 mRNA levels in both SLE and controls subjects 
(P=1.1×10-3 and 6.8×10-8 in linear regression, respectively; Figure 2A). No significant 
differences in SMG7 mRNA levels were observed between SLE patients and controls of the 
same genotype (genotype TT: P=0.34, CT: P=0.12, CC: P=0.87, SLE vs. controls in t test). The 
SNP rs12146097 was not significantly associated with SMG7 expression in our samples, which 
might be due to fewer carriers of the minor allele (MAF: 14% of rs12146097 compared to 37% 
of rs2275675 in Europeans; 1000 Genomes data).  
Long non-coding RNAs (lncRNAs, typically >200nt) are actively transcribed genes 
without protein-coding potential [30]. lncRNA expression often correlates with its cis protein-
coding genes, which is subject to strong eQTL regulation [31]. Located 0.4kb upstream of 
SMG7 is lncRNA SMG7-AS1 (SMG7 antisense RNA 1) and rs2275675 is in its second intron. 
Of interest, transcript levels of SMG7 and SMG7-AS1 were positively correlated in control 
PBMCs (r=0.60, P=3.5×10-9; Figure S3A). The risk allele of rs2275675 was also associated with 
decreased SMG7-AS1 levels (P=0.008, Figure S3B). 
Given that rs2275675 and its linked SNP rs10911339 (r2=1) are located in a region 
exhibiting epigenetic marks of active promoters/enhancers (Figure S2), we performed luciferase 
reporter assays to test their effects on transcription activity. Cell lysates transfected with the 
rs2275675 risk C-allele construct showed significantly lower luciferase activity than those 
transfected with the non-risk T-allele construct in both HEK-293 and Raji cells (P=0.0035 and 
0.0037, respectively; Figure 2B). There were no significantly allelic differences observed using 
the rs10911339 constructs (Figure 2C). Taken together, consistent results from ex vivo and in 
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vitro studies indicated that rs2275675 might best tag SLE-associated SNPs within the SMG7 
region to affect SMG7 expression, with the risk allele conferring decreased SMG7 mRNA levels. 
 
Decreased SMG7 levels associated with increased ANA titers 
The NMD pathway degrades mRNAs with premature termination codons (PTCs), 
preventing the production of truncated proteins that could function in dominant-negative or other 
deleterious mechanisms [32]. Given that SMG7, together with other SMGs, mediate the 
phosphrylation and dephosphorylation of UPF1 (a key effector of NMD) [33], we hypothesize 
that decreased SMG7 levels may affect the efficiency of NMD, thereby leading to accumulation 
of NMD-susceptible messenger ribonucleoprotein particles (mRNPs) and autoantibody 
production in SLE. To test this hypothesis, we first assessed the correlation of SMG7 mRNA 
levels and ANAs in 68 European-derived SLE patients. We observed a significant inverse 
correlation that patients with higher ANA titers had lower SMG7 mRNA levels in PBMCs (r=-
0.31, P=0.01; Figure 3A).  
Next, we performed siRNA-mediated knock down of SMG7 levels in SLE PBMCs to 
assess whether autoantibody production might be affected by SMG7 expression in vitro. To 
minimize confounding factors caused by disease activity or medications, the selected 13 
patients were all in clinical remission defined by SLE Disease Activity Index SELENA 
Modification (SELENA-SLEDAI) score <4 [34], prednisone dosage less than 15 mg/d and had a 
positive ANA at the time of blood draw. PBMCs from patients were cultured for 5 days in the 
presence or absence of siRNA targeting SMG7, GAPDH (as positive control), or siRNA with a 
non-targeting sequence (as negative control), respectively. After confirming the specific 
inhibition efficacy of SMG7 (Figure S4), we measured ANA levels in culture supernatants. 
Consistent with the ex vivo finding of inverse correlation between SMG7 levels and ANA titers in 
SLE patients, PBMCs treated with SMG7 siRNA showed a 7.6% increase in ANA production 
(P=2.0×10-5, as compared to the negative control group; Figure 3B). Given that autoantibody 
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production requires T, B cell help and some cyto/chemokines produced by T/B cells have been 
found to be overexpressed in SLE patients correlating with disease activity or autoantibody titers, 
we also tested if SMG7 was linked to the cyto/chemokine disturbance by measuring levels of 
CCL19, CXCL10, IL-6, IL-17, BAFF and IFN-α in culture supernatants. CCL19, an IFN-regulated 
chemokine that has been implicated as a biomarker for lupus activity [35], was significantly 
increased in the SMG7 siRNA treated group compared to those in the negative control group 
(P=2.0×10-4; Figure 3C). There were no differences in other tested cyto/chemokines between 
groups treated with specific siRNAs (Figure S5). Taken together, decreased SMG7 levels could 
affect the production of ANA and CCL19 in PBMCs of SLE patients, supporting a potential role 






By trans-ancestral fine mapping of the NMNAT2/SMG7 region, we confirmed previously GWAS 
reported association with SLE at the NMNAT2 locus and identified multiple SNPs located within 
the SMG7 locus showing strong and independent associations with SLE in EA ancestry. Of 
interest, the risk alleles of SLE-associated SNPs at both NMNAT2 and SMG7 loci showed 
association with decreased expression levels of SMG7, but not NMNAT2 in publically available 
eQTL datasets conducted in immune cells from European donors. Consistently, rs2275675, 
located in the SMG7 5’ regulatory region, was experimentally confirmed to best tag SLE-
associated SNPs within the SMG7 region affecting SMG7 expression, as shown by the risk 
allele dose-dependently associated with low SMG7 mRNA levels in PBMCs and reduced 
transcription activity in transfected cell lines. SLE patients with higher ANA titers had lower 
SMG7 mRNA levels in their PBMCs and inhibition of SMG7 expression increased ANA and 
CCL19 production in SLE PBMC cultures. Thus, our data demonstrated both NMNAT2 and 
SMG7 as SLE risk genes on 1q25 and implicated the NMD pathway affected by lowered SMG7 
expression promotes the development of SLE manifestation. 
The NMD, part of RNA surveillance pathways, post-transcriptionally regulates a 
considerable fraction of the transcriptomes [36]. PTC-containing mRNAs, arising from nonsense 
or frameshift mutations, errors in alternative splicing, or programmed DNA rearrangements 
occurred in T-cell receptor (TCR) and immunoglobulin (Ig) genes, comprise the major group of 
NMD substrates [33]. Truncated proteins encoded by such PTC-bearing mRNAs possess 
deleterious dominant-negative or gain-of-function activity in cells, so that an escape from NMD 
can result in clinical phenotypes [37]. In the case of SLE, rare mutations leading to production of 
PTC-containing mRNAs of DNASE1, DNASE1L3 and TREX1 have been associated with 
disease risk [38-40]. In addition, NMD can modulate the expression of approximate 10% of 
physiological mRNAs involved in diverse cellular processes, including spliceosomal components 
snRNP and Sm which are autoantigens in SLE patients [33, 41]. As a key component of the 
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NMD pathway, SMG7 interacts with SMG5 regulating the phosphorylation and 
dephosphorylation of UPF1 (a functional core of the NMD machinery) [33, 42]. Depletion of 
SMG7 or other SMG members could inhibit NMD activity in mammalian cells, resulting in 
enhanced expression levels of PTC-containing transcripts [43]. Based on these findings, we 
created a working hypothesis that inefficiency of NMD pathway attributable to decreased SMG7 
expression may cause accumulation of truncated proteins and mRNPs, leading to autoantibody 
production in SLE. Support evidence for this hypothesis included that a) low SMG7 mRNA 
levels were found to be correlated with high ANA titers in SLE patients, and b) inhibition of 
SMG7 expression increased ANA production in SLE PBMC cultures. However, in terms of 
subtypes of ANAs, we did not observe significant associations between SMG7 expression and 
anti-dsDNA, Ro/SSA, La/SSB, RNP or Sm antibodies, partially due to the limited sample size of 
seropositive patients (Figure S6). In addition to ANA, we also found elevated CCL19 production 
after silencing of SMG7 in SLE PBMCs, suggesting a potential role of SMG7 in regulation of 
CCL19 levels in SLE. CCL19, specifically binding to the chemokine receptor CCR7, promotes 
migration/interaction of B-Th cells, formation of germinal center and production of high-affinity, 
class-switched antibodies [44, 45]. How SMG7 depletion affects autoantibody and CCL19 
production are currently unclear. 
Based on imputation, multiple SNPs within the SMG7 locus were identified to be strongly 
associated with SLE in EA and their genetic effects were independent of those in the NMNAT2 
region. To our knowledge, our data provides the first evidence in support of SMG7 as a novel 
SLE risk gene in EA. The genotyping platform used in the published SLE European GWAS [2, 
46-48], which contained 10 SMG7 SNPs, could only capture 74 of the 115 common SNPs 
(MAF>1%) within +/- 5kb of SMG7 with r2>0.9 in EA (according to the 1000 Genome Project 
data), resulting in the absence of SMG7 association with SLE. In HS, the minor alleles of SMG7 
SNPs also showed higher frequencies in SLE patients than controls, similarly as in EA, but none 
reached the Bonferroni-corrected significance level (Table S2). Given the lack of evidence for 
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genetic heterogeneity across EA and HS (P>0.48 for Q statistic), insufficient statistical power 
due to the relatively small sample size might help explain the lack of association in HS (98% 
power in EA; 40% in HS). We did not detect significant association signals at NMNAT2/SMG7 
region in AA and AS datasets. It is possible that a) this region in these two ancestries was not 
imputed as well as in EA; and b) other SLE-associated variant(s) specific for AA and AS failed 
to be captured by SNPs used in this study due to different LD patterns. The association of 
NMNAT2/SMG7 with SLE in AA and AS awaits further investigation. 
The underlying causal SNP(s) driving association signals in the SMG7 region could not 
be identified using only genetic association study because of their strong LD strength. Based on 
the ENCODE functional annotation, these SLE-associated SNPs, especially rs2275675 and 
rs10911339, are located in a regulatory region with potential impact on gene regulation through 
alterations in transcriptional activity and epigenetic modifications. Consistent with results of 
eQTL datasets, the significant decreased levels of SMG7 mRNA in PBMCs from individuals 
carrying the SLE-risk C allele of rs2275675, along with the notable lower level of C-allele 
containing luciferase reporter activity, supported that rs2275675 might best tag SLE-associated 
SMG7 SNPs affecting SMG7 expression. Further analysis by the HaploReg database predicted 
allelic differences of rs2275675 in binding to a transcription factor THAP1 that encodes THAP 
domain-containing apoptosis associated protein 1 with functions involved in endothelial cell 
proliferation and proapoptotic processes [49, 50]. The exact molecular mechanism by which 
rs2275675 may regulate SMG7 expression is therefore yet to be experimentally validated. 
The association of NMNAT2 with SLE at rs2022013, previously identified by the 
SLEGEN GWAS in EA, was confirmed in our independent EA subjects only. Under the 
assumption that the minor allele of rs2022013 confers genetic risk with an odds ratio of 0.83 
(determined in EA), the power to detect a significant association (P<1×10-3) for EA samples 
reaches 97%, but only 36% in HS, 43% in AS and 51% in AA datasets. In addition to rs2022013, 
we identified 6 SNPs within a small interval in the NMNAT2 intron 1 exhibiting consistent and 
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strong association with SLE in EA and HS. In HS, all other NMNAT2 associations with SLE 
were eliminated or reduced to baseline after conditioning test, suggesting that underlying causal 
variant(s) at NMNAT2 could be captured by these 6 SNPs. However, similar conditioning test in 
EA revealed residual associations, requiring further refinement of genetic effects within 
NMNAT2 to localize putative causal variant(s) in EA. 
Proximity to the NMNAT2/SMG7 region at 1q25 is NCF2, encoding a subunit of NADPH 
(nicotinamide adenine dinucleotide phosphate) oxidase complex involved in the reactive oxygen 
species (ROS) generation. Genetic associations of NCF2 with SLE include three non-
synonymous SNPs (H389Q that leads to reduced NADPH oxidase activity and ROS production, 
R395W and V297A) and three intronic variants (rs10911359, rs34423782 and rs34680162) [51, 
52]. None of them showed strong LD with SNPs at the NMNAT2/SMG7 locus according to the 
1000 Genome Project data (Figure S7). Association signals within the NMNAT2/SMG7 region in 
EA and HS identified by this study may not be driven by SLE-associated SNPs at NCF2. 
In summary, we confirmed previous GWAS reported NMNAT2 association with SLE and 
identified SMG7 as a novel risk gene for SLE in EA. Our data showed a link between SLE-
associated variants in the NMNAT2/SMG7 locus and decreased SMG7 mRNA levels, and 
provided evidence for functional relevance of SMG7 in production of ANA and chemokines in 
SLE. Given SMG7 encoding a protein involved in the NMD pathway, our study implicates the 
novel contribution of this important regulatory pathway to the SLE pathogenesis. Further 









Figure 1. Association of SNPs in the NMNAT2/SMG7 region with SLE. (A) The genomic 
structure of the NMNAT2/SMG7 region and positions of genetic variants are indicated. (B) The 
allelic P value (−log10P value) of each genetic variant with SLE is plotted against its position as a 
circle (genotyped) or a triangle (imputed) for European American (EA), Amerindian/Hispanic 
(HS), African American (AA) and Asian (AS), respectively. Genetic variants are highlighted 
using different colors according to their strength of linkage disequilibrium (r2) with rs2022013 
(shown as a blue diamond). The dashed line represents a Bonferroni corrected P<1×10-3. 
Arrows identify rs2022013 and SNPs demonstrating the most significant association signals in 
each ancestry. Black rectangle identifies group 2 SNPs at SMG7 locus strongly associated with 
SLE in EA and the best-associated SNP rs2702178 is indicated. (C) Trans-ancestral meta-
analysis is conducted on 8 SNPs that remain significant associations after Bonferroni correction 
in both EA and HS. Black rectangle identifies group 1 SNPs at the NMNAT2 intron 1 showing 
Pmeta values exceeding the GWAS significance level. The dashed line represents the 
significance level of 5×10-8.  
 
Figure 2. The SLE-risk C allele of rs2275675 associated with decreased SMG7 
expression. (A) Association of rs2275675 genotypes with SMG7 mRNA levels in PBMCs from 
European-derived SLE patients and healthy controls, respectively. Box plots show median, 
upper and lower quartiles, with whiskers denoting 10% and 90% percentiles. Outlying values 
are shown in black symbols. (B&C) Allelic differences of rs2275675 and rs10911339 in 
luciferase activity. Data show the mean ± SEM results of three independent experiments. 
 
Figure 3. Decreased SMG7 levels associated with increased ANA production. (A) Inverse 
correlation of ANA titers and SMG7 mRNA levels in patients with SLE. (B&C) Increased ANA 
and CCL19 levels after SMG7 silencing in SLE PBMCs. PBMCs from ANA positive SLE patients 
(n=13) were incubated for 5 days in the presence or absence of siRNA targeting SMG7, 
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GAPDH or siRNA with a non-targeting sequence (NC), respectively. ANA (B) and CCL19 (C) 
levels in the culture supernatants were measured by ELISA, and plotted as fold change with 
respect to mock (culture medium only). Results are presented as mean ± SEM. 
 
Figure S1. Conditional association testing between SNPs in the NMNAT2 and SMG7 
region in EA. Six SNPs in the NMNAT2 region showing a combined Pmeta<5×10-8 in the trans-
ancestral meta-analysis of EA and HS ancestries and 21 SNPs within the SMG7 region showing 
strong association with SLE in EA are named as group 1 and group 2, respectively. The dashed 
line represents the significance level of P=0.05. 
 
Figure S2. Bioinformatic analyses of the SLE-associated SNPs identified in EA. The 
Encyclopedia of DNA Elements (ENCODE) Integrated Regulation super-track in the UCSC 
Genome browser is used to evaluate overlap between genomic regulatory elements and the 
SLE-associated group1 (A) and group 2 SNPs (B). The super-track contains information on 
gene transcription, DNase hypersensitivity clusters, ChIP-seq defined transcription factor 
binding regions and histone marks consistent with promoter/enhancer regions from multiple cell 
lines. For histone modifications, DNase hypersensitivity and transcription factor clusters, signal 
values are shown as grayscale-colored items, with the darkness of the box proportional to the 
signal strength observed in any cell line. Arrows identify group 2 SNPs rs2275675 and 
rs10911339 (r2=1) showing strong overlap with regulatory elements. 
 
Figure S3. SMG7-AS1 expression associated with SMG7 and rs2275675. (A) Transcript 
levels of SMG7-AS1 and SMG7 were positively correlated in PBMCs from healthy controls. (B) 





Figure S4. Decreased SMG7 mRNA levels by SMG7 siRNA in PBMCs. PBMCs from SLE 
patients (n=13) were incubated for 5 days in the presence or absence of siRNA targeting SMG7, 
GAPDH, or siRNA with a non-targeting sequence (NC), respectively. The percentages of viable 
cells were >90% before and after the culture, and no differences were observed in cell viability 
among groups. SMG7 (A) and GAPDH (B) mRNA levels were measured by RT-PCR, and 
plotted as fold change with respect to mock (culture medium only). A 76.3% reduction of SMG7 
mRNA levels was observed only in culture cells treated with siRNA specific for SMG7, while a 
77.6% reduction of GAPDH mRNA levels was detected only in the positive control group treated 
with GAPDH siRNA. Results are presented as mean ± SEM. 
 
Figure S5. Production of cytokines and chemokines after SMG7 silencing in SLE PBMCs. 
PBMCs from SLE patients (n=13) were incubated for 5 days in the presence or absence of 
siRNA targeting SMG7, GAPDH or siRNA with a non-targeting sequence (NC), respectively. 
CXCL10 (A), IL-6 (B), IL-17 (C), BAFF (D) and IFN-α (E) levels in the culture supernatants were 
measured by ELISA, and plotted as fold change with respect to mock (culture medium only). 
Results are presented as mean ± SEM. 
 
Figure S6. No association between SMG7 expression and anti-dsDNA, Ro/SSA, La/SSB, 
RNP or Sm antibodies. Each symbol represents an individual sample and horizontal lines 
show mean ± SEM values. 
 
Figure S7. LD and frequencies of SLE-associated SNPs at the NMNAT2/SMG7 and NCF2 
region. (A) Pairwise LD values (r2) of SLE-associated SNPs at the NMNAT2/SMG7 and NCF2 
region in each ancestry according to the 1000 Genome Project Data. (B) SNP frequency in each 
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Table S1. Allelic association of NMNAT2/SMG7 SNPs with SLE in European American 
        
Teste
d 
Frequency       
Typ





















































































































































































































































































































































        
Teste
d 
Frequency       
Typ













































































































































































































































































































































































        
Teste
d 
Frequency       
Typ
































































































































































































































































































































































































        
Teste
d 
Frequency       
Typ




















































































































































































































































































































































































































        
Teste
d 
Frequency       
Typ
























































































































































































































































































































































































        
Teste
d 
Frequency       
Typ






















































































































































































































































































































































































        
Teste
d 
Frequency       
Typ


















































































































































































































































































































































































        
Teste
d 
Frequency       
Typ


































































































































































































































































































































































































        
Teste
d 
Frequency       
Typ




































































































































































































































































































































        
Teste
d 
Frequency       
Typ


































































































































































































If P reached the Bonferroni-corrected significance level of 1.0×10-3, it is highlighted in bold and italic. Position of each SNP is based 
on GRch37/hg19.  
21 SNPs within the SMG7 region that showed strong association with SLE with P values around the GWAS significance level 
(named as group 2) are shaded in gray. 
G, genotyped SNP; I, imputed SNP; ND, non-distinguishable in conditional testing; Pc, P value after conditioning on six SNPs 





Table S2. Allelic association of NMNAT2/SMG7 SNPs with SLE in Amerindian/Hispanics 
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If P reached the Bonferroni-corrected significance level of 1.0×10-3, it is highlighted in bold and italic. Position of each SNP is based 
on GRch37/hg19.  
G, genotyped SNP; I, imputed SNP; ND, non-distinguishable in conditional testing; Pc, P value after conditioning on six SNPs 






Table S3. Allelic association of NMNAT2/SMG7 SNPs with SLE in African American 
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NMNAT2 intron 1 T 33.6% 32.6% 0.62 
1.03[0.93-
1.14] 
I rs6672141 18326664 NMNAT2 intron 1 A 23.8% 23.1% 0.65 1.03[0.92-
47 
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C 15.5% 16.8% 0.16 
0.91[0.79-
1.04] 






Table S4. Allelic association of NMNAT2/SMG7 SNPs with SLE in Asian 
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I rs58734925 18323417 NMNAT2 intron 8 G 20.8% 22.1% 0.2 0.92[0.80-
51 
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Frequency     





P OR [95%CI] 
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Table S5. Significant association of SNPs with SLE in European American and Amerindian/Hispanics 
        
Teste
d 























































































































































Only SNPs that remain significant associations with SLE after Bonferroni correction in both EA and HS are listed in this table. SNPs 
that show a combined Pmeta<5×10
-8 in the trans-ancestral meta-analysis (named as group 1) are highlighted in gray. 





Table S6. Association between low SMG7 mRNA levels and the SLE-risk allele of tag SNPs in eQTL 
databases 
Study SNP Group Tag SNP SLE-Risk Allele P value for each SMG7 Probe Cells 





































Dimas et al, 2009 [16] 
1 rs12146097 T NS NS 10-4 F 
2 rs10911353 A NS NS 10-5~10-9 L, T 
Nica et al, 2011 [17] 
1 rs502870 G NS NS 10
-5 L 
2 rs2275675 C NS NS 10
-7~10-10 L, A 
2 rs10911353 A NS NS 10
-7~10-10 L, A 
Stranger et al, 2012 [18] 
1 rs12146097 T NS NS NA L 
1 rs502870 G NS 10-4 NA L 
2 rs2275675 C NS 10-4 NA L 
2 rs10911353 A NS 10-4 NA L 
Fairfax et al, 2012 [19] 
1 rs664422 T NA NS 10
-8~10-9 B, M 
2 rs2275675 C NA 10
-8~10-13 10-32~10-47 B, M 
Westra et al, 2013 [20] 
1 rs12146097 T NA 10-17 10-34 P 
1 rs502870 G NA 10
-32 10-80 P 
2 rs2275675 C NA 10-198 10-198 P 
2 rs10911353 A NA 10
-198 10-198 P 
A, adipocytes; B, primary B cells; F, fibroblasts; L, lymphoblastoid cell lines; M, primary monocytes; P, peripheral blood cells;  
T, primary T cells. NA, not available; NS, not significant.  
 
 
